Herpes labialis (HL) is the most common manifestation of recurrent oral herpes simplex virus type-1 (HSV-1) infection. Between 20% and 40% of the population is affected by recurrent HL. The biological basis for the difference between HSV-1-infected individuals who do and who do not suffer recurrences, has long been investigated. Interferon (IFN)-α and IFN-λ are essential for antiviral immunity, but the precise role of IFN-λ in vivo is not yet well understood.
Methods
Healthy immunocompetent patients with or without a history of recurrent HL were recruited from the Policlinico of the University of Rome Tor Vergata (Rome, Italy), and HSV-1-seronegative individuals were recruited from the Department of Experimental Medicine of the University of Rome Tor Vergata, between July 2007 and December 2008. Participants were interviewed by medically trained investigators and underwent a blood test. Peripheral blood mononuclear cells (PBMCs) were obtained from heparinized blood of patients and stimulated in vitro with intact HSV-1 strain F1 (1 plaque-forming unit/cell). PBMC supernatants were assayed for IFN-α, IFN-γ and IFN-λ. production by ELISA at 24 and 48 h after viral challenge.
Results
PBMC from patients with a history of recurrent HL produced markedly lower levels of IFN-λ. and marginally lower levels of IFN-α and IFN-γ than those from the history-negative HSV-1-seropositive controls. Among individuals with HL recurrences, those with more frequent and severe manifestations showed a significant trend towards lower levels of IFN-λ production.
Conclusions
A reduced IFN-λ response might correlate with the development of recurrent HSV-1 infection in immunocompetent individuals. Testing for IFN-λ response might be useful to predict individual patterns of antiviral response, contributing to more successful therapeutic or prophylactic interventions.
References
1.
WhitleyR.J.Herpes simplex virus. In Virology. FieldsB.N., KnipeD.M., ChanockR.M. (Editors.) New York: Raven Press1990; pp. 1843–1887.
2.
NahmiasA.J., LeeF.K., Beckman-NahmiasS.Seroepidemiological and sociological patterns of herpes simplex virus infection in the world.Scand J Infect Dis Suppl1990; 69: 19–36.
3.
HigginsC.R., SchofieldJ.K., TatnallF.M.Natural history, management and complications of herpes labialis.J Med Virol1993; 41 Suppl 1: 22–26.
4.
SpruanceS.L., ChouF.Pathogenesis of herpes simplex labialis.J Infect Dis1980; 142: 671–675.
KliemanR.L., GreenJ.A., SpruanceS.L.Immunostimulatory function of herpes simplex virus isolates from patients with frequent herpes labialis and a deficiency in immune specific interferon production.J Med Virol1985; 16: 289–296.
WildyP., GellP.G.H.The host response to herpes simplex virus.Br Med Bull1985; 41: 86–91.
9.
WiltonJ.M.A., IvanyiL., LehnerT.Cell-mediated immunity in herpesvirus hominis infection.BMJ1972; 1: 723–726.
10.
O'ReillyR.J., ChibbaroA., AngerE., LopezC.Cell-mediated immune responses in patients with recurrent herpes simplex infections.J Immunol1977; 118: 1095–1102.
11.
ShillitoeE.J., WiltonJ.M.A., LehnerT.Sequential changes in cell-mediate immune responses to herpes simplex virus after recurrent herpetic infection in humans.Infect Immun1977; 18: 130–137.
12.
RattrayM.C., PetermanG.M., AltmanL.C., CoreyL., HolmesK.K.Lymphocyte-derived chemotactic factor synthesis in initial genital herpesvirus infection: correlation with lymphocyte transformation.Infect Immun1980; 30: 110–116.
13.
CunninghamA.L., MeriganT.C.Interferon production appears to predict time of recurrence of herpes labialis.J Immunol1983; 130: 2397–2399.
14.
GreenJ.A., WeissP.N., YekT.J., SpruanceS.L.Immune specific interferon production by peripheral blood mononuclear leukocytes from humans with primary and recurrent orolabial herpes simplex virus infections.J Med Virol1985; 16: 297–305.
15.
SheridanJ.F., BeckB., SmithC.C., AurelianL.Reactivation of herpes simplex virus is associated with production of a low molecular weight factor that inhibits lymphokine activity in vitro.J Immunol1987; 138: 1234–1239.
16.
KuoY.C., LinC. Y.. Recurrent herpes simplex virus type I infection precipitated by the impaired production of interleukin-2, alpha-interferon, and cell-mediated immunity.J Med Virol1990; 31: 183–189.
17.
SpruanceS.L., EvansT.G., McKeoughM.B.Th1/Th2-like immunity and resistance to herpes simplex labialis.Antiviral Res1995; 28: 39–55.
18.
KotenkoS.V., GallagherG., BaurinV.V.IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex.Nat Immunol2003; 4: 69–77.
19.
SheppardP., KindsvogelW., XuW.IL-28, IL-29, and their class II cytokine receptor IL-28R.Nat Immunol2003; 4: 63–68.
20.
DoyleS.E., SchreckhiseH., Khuu-DuongK.Interleukin-29 uses a type I interferon-like program to promote antiviral responses in human hepatocytes.Hepatology2006; 44: 896–906.
21.
ZhouZ., HammingO.J., AnkN., PaludanS.R., NielsenA.L., HartmannR.Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells though signaling pathways involving both Jak-STAT pathway and the mitogen-activated protein kinases.J Virol2007; 81: 7749–7758.
22.
MarcelloT., GrakouiA., Barba-SpaethG.Interferons α and λ inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics.Gastroenterology2006; 131: 1887–1898.
23.
RobekM.D., BoydB.S., ChisariF.V.Lambda interferon inhibits hepatitis B and C virus replication.J Virol2005; 79: 3851–3854.
24.
BrandS., BeigelF., OlszakT.IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression.Am J Physiol Gastrointest Liver Physiol2005; 289: G960–G968.
25.
AnkN., WestH., BartholdyC., ErikssonK., ThomsenA.R., PaludanS.R.Lambda-interferon (IFN-λ), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against selected virus infection in vivo.J Virol2006; 80: 4501–4509.
26.
HouW., WangX., YeL.Lambda interferon inhibits human immunodeficiency virus type I infection of macrophages.J Virol2009; 83: 3834–3842.
27.
ContoliM., MessageS.D., Laza-StancaV.Role of deficient type III interferon-λ production in asthma exacerbations.Nat Med2006; 12: 1023–1026.
28.
La FraziaS., AmiciC., SantoroM.G.Antiviral activity of proteasome inhibitors in herpes simplex virus-1 infection: role of nuclear factor-kappaB.Antivir Ther2006; 11: 995–1004.
KoelleD.M., CoreyL.Herpes simplex: insights on/into pathogenesis and possible vaccines.Annu Rev Med2008; 59: 381–395.
31.
SeppanenM., MeriS., NotkolaI-L. Subtly impaired humoral immunity predispose to frequently recurring genital herpes simplex virus type 2 infection and herpetic neuralgia.J Infect Dis2006; 194: 571–578.
32.
KittanN.A., BerguaA., HauptS.Impaired plasmacytoid dendritic cell innate immune responses in patients with herpes virus-associated acute retinal necrosis.J Immunol2007; 179: 4219–4230.
33.
CasrougeA., ZhangS-Y, EidenschenkC.Herpes simplex encephalitis in human UNC-93B deficiency.Science2006; 314: 308–312.
34.
SiegalF.P., KadowakiN., ShoddellM.The nature of the principal type I interferon-producing cells in human blood.Science1999; 284: 1835–1837.
35.
CellaM., JarrossayD., FacchettiF.Plasmacytoide monocytes migrate to inflammed lymphnodes and produce large amounts of type I interferon.Nat Med1999; 5: 919–923.
LundJ., SatoA., AkiraR.Medzhitov, and Iwasaki A. Tolllike receptor 9-mediated recognition of herpes simplex-2 by plasmacytoid dendritic cells.J Exp Med2003; 198: 513–520.
38.
HochreinH., SchlatterB., O'KeeffeM.Herpes simplex virus type-I induces IFN-α production via Toll-like receptor 9-dependent and -independent pathways.Proc Natl Acad Sci U S A2004; 101: 11416–11421.
39.
TabetaK., HoebeK., JanssenE.M.The Unc93b1 mutation 3d disrupts exogenous antigen presentation and signaling via Toll-like receptors 3, 7 and 9.Nat Immunol2006; 7: 156–164.
40.
ZhangS-Y, JouanguyE., Sancho-ShimizuV.Human Toll-like receptor-dependent induction of interferons in protective immunity to viruses.Immunol Rev2007; 220: 225–236.
41.
ZhangS.Y., Boisson-DupuisS., ChapgierA.Inborn errors of interferon (IFN)-mediated immunity in humans: insights into the respective roles of IFN-alpha/beta, IFN-gamma, and IFN-lambda in host defence.Immunol Rev2008; 226: 29–40.
BironC.A.Initial and innate responses to viral infections-pattern setting in immunity or disease.Curr Opin Microbiol1999; 2: 374–381.
44.
Asselin-PaturelC., TrinchieriG.Production of type I interferons: plasmacytoid dendritic cells and beyond.J Exp Med2005; 202: 461–465.
45.
HansmannL., GroegerS., von WulffenW., BeinG., HacksteinH.Human monocytes represent a competitive source of interferon-a in peripheral blood.Clin Immunol2008; 127: 252–264.
46.
CocciaE.M., SeveraM., GiacominiE.Viral infection and Toll-like receptor agonists induce a differentiated expression of type I and λ interferons in human plasmacytoid and monocyte-derived dendritic cells.Eur J Immunol2004; 34: 796–805.
47.
AnkN., IversenM.B., BartholdyC.An important role for type III interferon (IFN-λ/IL-28) in TLR-induced antiviral activity.J Immunol2008; 180: 2474–2485.
48.
LasfarA., Lewis-AntesA., SmirnovS.V.Characterization of the mouse IFN-λ ligand-receptor system: IFN-λs exhibit antitumor activity against B16 melanoma.Cancer Res2006; 66: 4468–4477.
49.
MennechetF.J., UzeG.Interferon λ-treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells.Blood2006; 107: 4417–4423.
PengT., ZhuJ., KlockA.Evasion of the mucosal innate immune system by herpes simplex virus type 2.J Virol2009; 83: 12559–12568.
52.
MilliganG.N., BernsteinD.I.Interferon-gamma enhances resolution of herpes simplex virus type 2 infection of the murine genital tract.Virology1997; 229: 259–268.
